Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis
about
Current and emerging azole antifungal agentsUpregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitorsComparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeastsIn vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.Discovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossingEvaluation of Virulence Factors In vitro, Resistance to Osmotic Stress and Antifungal Susceptibility of Candida tropicalis Isolated from the Coastal Environment of Northeast Brazil.Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins.Clinical evaluation of the ASTY colorimetric microdilution panel for antifungal susceptibility testing.Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.One year prospective survey of Candida bloodstream infections in Scotland.Multicenter comparison of the sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus sppFluconazole susceptibilities of bloodstream Candida sp. isolates as determined by National Committee for Clinical Laboratory Standards method M27-A and two other methodsOptimizing voriconazole susceptibility testing of Candida: effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility.Quantitation of ergosterol content: novel method for determination of fluconazole susceptibility of Candida albicansMicrodilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium speciesQuality control limits for broth microdilution susceptibility tests of ten antifungal agents.Influence of glucose supplementation and inoculum size on growth kinetics and antifungal susceptibility testing of Candida sppPrevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada.Fluconazole and voriconazole multidisk testing of Candida species for disk test calibration and MIC estimation.Standardization of antifungal susceptibility variables for a semiautomated methodology.Novel fluorescent broth microdilution method for fluconazole susceptibility testing of Candida albicans.Antifungal susceptibility testing: practical aspects and current challenges.The trailing end point phenotype in antifungal susceptibility testing is pH dependentA new azole derivative of 1,4-benzothiazine increases the antifungal mechanisms of natural effector cellsExperimental induction of fluconazole resistance in Candida tropicalis ATCC 750Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis.In vivo activity of amphotericin B lipid complex in immunocompromised mice against fluconazole-resistant or fluconazole-susceptible Candida tropicalis.Sensitive bioassay for determination of fluconazole concentrations in plasma using a Candida albicans mutant hypersusceptible to azoles.T-2307 shows efficacy in a murine model of Candida glabrata infection despite in vitro trailing growth phenomena.Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailinComparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of candida species.Comparative evaluation of a new fluorescent carboxyfluorescein diacetate-modified microdilution method for antifungal susceptibility testing of Candida albicans isolates.Fluconazole treatment is effective against a Candida albicans erg3/erg3 mutant in vivo despite in vitro resistance.ROX1 and ERG regulation in Saccharomyces cerevisiae: implications for antifungal susceptibilityIn vitro activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical Candida isolatesCorrelation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazoleValidation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance programDefined anaerobic growth medium for studying Candida albicans basic biology and resistance to eight antifungal drugs.Trafficking through the late endosome significantly impacts Candida albicans tolerance of the azole antifungals.Antifungal effects on metabolite profiles of medically important yeast species measured by nuclear magnetic resonance spectroscopy.
P2860
Q24550733-1B457559-BE68-4E63-82E6-21CE92EB495CQ28344744-315CADE8-64B7-431F-BBCF-3221B5AC3730Q28368930-B06450EF-2F62-49C2-BE0F-4D86A7880065Q28379300-6FEE66F5-2218-4D2C-91C8-5C6E78D239C0Q28485433-52794549-2C0E-4328-A6C5-3AE885B3584EQ30828568-F48CEF06-B990-4F34-826C-C9CBDE93CC7DQ31058690-BAAB91F4-5344-4FFB-BC01-6FB1654796C7Q33682650-6E49F39F-BDEF-4665-8BBE-9C84C68734BEQ33721804-DBCD5F03-5DCE-4189-AEDD-72DB5CA28115Q33910250-7A06AA79-A800-4157-87F5-6EA39859E1CFQ33959197-7AF99D87-1168-4C37-B7E7-F498120A34CAQ33961413-0354F2BA-4879-45C6-B3E5-050488776CF4Q33962343-31AE647E-D4CB-4ACC-B7BA-AA2FCEE8005DQ33963057-EE9EAEE8-D453-4763-89EC-3A829E6E55D2Q33964175-4338168B-2B93-490C-8243-79074DD4B760Q33969748-FA6F4A03-0797-4DE3-925E-C61B89E0A146Q33971165-A43252C7-1E2C-4564-85D8-9FE56C0B8A99Q33971521-10B97E2E-A5B2-4D46-9A07-E29A654067C4Q33971918-37CFED81-FE92-4602-85F8-048484E9EC11Q33972874-A745A466-7A64-4E77-9632-B2E9E4E8A152Q33973011-5F1D0471-B3F3-4F53-91C4-EE49BC6EB060Q33975757-61872FC5-EB68-438B-B980-A6CBB28850D7Q33976909-1C059609-BF89-4401-90FB-7AE787FBED5CQ33977602-8E25D276-AD4F-4CB6-B80B-06BA9B7CEFA6Q33979724-B4738CDA-CBF6-49CD-9360-2810803EDDC7Q33980195-297586D0-EC6D-475A-A4B8-9E1B18067D82Q33980705-34660A48-A352-4234-9634-EB1E1064F770Q33981566-6CD94252-0C72-4CAE-8695-E4A39FF470C4Q34108719-C1F0D3C9-F940-4E88-9D43-1FA47ECDC364Q34110565-599AE461-7941-4560-8EDD-DF421151C53CQ34142465-FA065F6D-B1FD-42D8-9E3D-B8FDC3502229Q34143149-7C5A3D76-484F-4BA8-8B81-9F8C9B831B29Q34352293-069C54AB-4ACA-47E1-B0BA-5809B05BC6E8Q34420719-2059467A-6F9A-4382-A6E8-18A2C921A8ADQ34452652-2ACB4190-356B-4F1A-99C9-65CF3A198DF5Q34941412-FD96CA0E-83B6-422C-BC36-14E39D64BE43Q35067016-4FFBAABB-B001-43FA-A661-8B4E1A37C0BCQ35125877-17213FC5-343E-4CB0-A46A-F845F12DFD11Q35168990-E0C0E9F4-EC25-440A-ADAF-27B4591B689EQ35215404-2E30C688-6EF2-462D-99DA-6C5BC795C509
P2860
Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Optimizing the correlation bet ...... model of invasive candidiasis
@ast
Optimizing the correlation bet ...... model of invasive candidiasis
@en
type
label
Optimizing the correlation bet ...... model of invasive candidiasis
@ast
Optimizing the correlation bet ...... model of invasive candidiasis
@en
prefLabel
Optimizing the correlation bet ...... model of invasive candidiasis
@ast
Optimizing the correlation bet ...... model of invasive candidiasis
@en
P2093
P2860
P1476
Optimizing the correlation bet ...... model of invasive candidiasis
@en
P2093
A Espinel-Ingroff
E J Anaissie
M Lozano-Chiu
P W Nelson
V L Paetznick
P2860
P304
P407
P577
1998-01-01T00:00:00Z